Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with or without Interferon in Metastatic Renal Cell Carcinoma
NCT00126594Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2005
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in renal cell carcinoma (RCC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 12 months and Adverse Events up to 12 months. Started Jun 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00126594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126594.